Clinical features of consecutive intramammary infections with Streptococcus agalactiae in vaccinated and non-vaccinated heifers

The clinical, haematological and functional changes which followed three consecutive intramammary infections of Streptococcus agalactiae in the first lactation of eight heifers, four of which were systemically hyperimmune to the organism, are described. Irrespective of whether it was a vaccinated or non-vaccinated heifer or first, second or third infection the clinical features during the first 24 hours were characterised by elevated temperatures with hard, swollen and painful infected quarters. First infections were almost all of short duration because of self cure, while second or third infections were prolonged, with intermittent excretion of bacteria and low cell counts. Milk yields of infected quarters were depressed, ranging from 8 per cent in short infections to 31 per cent in chronic infections. All blood parameters remained within normal limits with the exception of total and differential white cell counts, which showed a change from a quantitative to a qualitative response by the third infection. The most significant finding was the absence of any real difference between the systemically hyperimmune and the non-vaccinated heifers, suggesting that circulating antibody has little effect against intramammary infection.     

Cardiopulmonary and anesthetic effects of medetomidine-ketamine-butorphanol and antagonism with atipamezole in servals (Felis serval).

Seven (three male and four female) 4-7-yr old captive servals (Felis serval) weighing 13.7 +/- 2.3 kg were used to evaluate the cardiopulmonary and anesthetic effects of combined intramuscular injections of medetomidine (47.4 +/- 10.3 microg/kg), ketamine (1.0 +/- 0.2 mg/kg), and butorphanol (0.2 +/- 0.03 mg/kg). Inductions were smooth and rapid (11.7 +/- 4.3 min) and resulted in good muscle relaxation. Significant decreases in heart rate (85 +/- 12 beats/min) at 10 min after injection and respiratory rate (27 +/- 10 breaths/min) at 5 min after injection continued throughout the immobilization period. Rectal temperature and arterial blood pressure did not change significantly. The PaO2 decreased significantly, and PaCO2 increased significantly during immobilization but remained within clinically acceptable limits. Hypoxemia (PaO2 < 60 mm Hg) was not noted, and arterial blood oxygen saturation (SaO2) was greater than 90% at all times. Relative arterial oxygen saturation (SpO2) values, indicated by pulse oximetry, were lower than SaO2 values. All animals could be safely handled while sedated. Administration of atipamezole (236.8 +/- 51.2 microg/kg half i.v. and half s.c.), an alpha2 antagonist, resulted in rapid (4.1 +/- 3 min to standing) and smooth recoveries.     

Use of mycobacterial peptides and recombinant proteins for the diagnosis of bovine tuberculosis in skin test-positive cattle

More accurate tests are required to test cattle which have reacted positively in the tuberculin skin test. For this purpose, a range of mycobacterial antigens, MPB59, MPB64, MPB70, MPB83, ESAT-6 and CFP10, were used either as recombinant proteins or as synthetic peptides in the whole blood interferon-gamma (IFN-gamma) test. Groups of uninfected cattle with typical 'non-specificity' problems were targeted, in particular animals with skin tuberculosis, animals vaccinated against Johne's disease and animals that were positive in the standard purified protein derivative (PPD)-based IFN-gamma test. The two study groups consisted of 74 Mycobacterium bovis-culture positive animals and 72 uninfected animals, all of which tested positive in the caudal fold tuberculin skin test eight to 28 days before the blood test. The use of combinations of ESAT-6 and CFP10 antigens, either as recombinant proteins or peptides, detected similar percentages of M bovis-infected animals as the PPD-based IFN-gamma test, but produced significantly fewer false positive reactions. The PPD-based IFN-gamma test was very effective in differentiating animals vaccinated against Johne's disease that were skin-test positive from those with bovine tuberculosis, and the use of PPD or specific mycobacterial antigens minimised the number of false positive reactions in animals with skin tuberculosis.     

Sensitivity, specificity, and predictive values of ClinEase-Virastat saliva test for feline leukemia virus infection

Detection of virus in saliva using a commercial enzyme-linked immunosorbent assay (ELISA), ClinEase-VirastatR, was compared to evidence of FeLV infection by the indirect immunofluorescent antibody assay (IFA) and plasma ELISA. The sensitivity and specificity of the saliva ELISA were derived by comparison to IFA and plasma ELISA in 103 cats from a large colony in New York State. The sensitivity of the saliva test in relation to IFA and plasma ELISA was approximately 100% and 93%, respectively. The specificity of the saliva ELISA in relation to IFA and plasma ELISA was approximately 85% and 92%, respectively. This test appears to be particularly suitable as a screening test for FeLV infection, especially in populations where the expected prevalence is low. Because of its high sensitivity, the saliva test has a high negative predictive value, particularly in populations where the disease is rare. Since the specificity is moderate, however, the predictive value of a positive test will be poorest in cats originating from places where the infection is rare (e.g. single cat households, or free roaming cats), and better among cats from environments having a high prevalence of FeLV (e.g. multiple-cat households).     

Long-term follow-up study of cats vaccinated with a temperature-sensitive feline infectious peritonitis vaccine.

The long-term safety of a temperature-sensitive feline infectious peritonitis (FIP) vaccine was evaluated. Five hundred eighty-two healthy cats of various age groups were vaccinated with 2 doses of the vaccine. Seventy-eight percent, or 453 cats, were available for follow-up. The mean follow-up period was 541 days. At the end of the follow-up period, 427 cats (94%) were alive. FIP was not diagnosed in any cat during the follow-up period, but 1 cat died of FIP after completion of the follow-up period. Fifty cats (11%) presented with a problem during the follow-up period, but there were typical of those seen in a feline practice. The temperature-sensitive FIP vaccine appears to be safe for use in the general cat population. It does not appear to sensitize cats to develop FIP, nor do there appear to be any other systemic problems associated with use of the vaccine.